Sunday the 25th of March 2018
Australian Times


Medical Innovators: AXIM Biotech’s Proprietary cGMP Extraction and Manufacturing Approach Revolutionizes Industry

March 9, 2018 by Richard Cox in Health with 0 Comments

The world of medical marijuana research is rapidly changing, and recent news within the industry shows that some important innovations have developed which could revolutionize the landscape.

AXIM® Biotechnologies (OTC:AXIM) (“AXIM”), the world leader in cannabinoid research and development, recently announced the first-ever successful execution of proprietary current good manufacturing practices (“cGMP”) methods to extract and microencapsulate cannabinoid molecules for a variety of pharmaceutical delivery formats from cGMP-produced medicinal cannabis.

The breakthrough makes AXIM the only company in the world with the ability to harness the proprietary procedure and provide Active Pharmaceutical Ingredients (“APIs”) of such purity from naturally extracted cGMP sources.

Unprecedented Methods

AXIM’s new methods are unprecedented in terms of the nature of the process – which utilizes cGMP standards employed from the initial growing of the cannabis plants through extraction and manufacturing – leading to the highest of quality standards for APIs being met.

The process, which was developed and tested in the Netherlands under strict regulatory guidelines,  involves the growing of selected cannabis plants at a cGMP facility followed by extraction of the APIs from cannabis flowers in an innovative process that employs just two steps in order to achieve an average of more than 99% purity – unlike traditional methods that include toxic solvents and multiple steps to produce the final extract or synthesize an API such as dronabinol.


AXIM’s newly developed microencapsulation method is then applied to the cannabinoids, protecting those from oxidation and degradation, while preserving its effectiveness. Finally, AXIM’s microencapsulated cannabinoids are manufactured into pharmaceutical products within different delivery format categories such as chewing gum, suppositories, transdermal delivery systems, etc.

“We’re thrilled to be able to announce this new method to the industry,” said George E. Anastassov, MD, DDS, MBA, and Chief Executive Officer of AXIM Biotech. “Our innovative extraction process achieves reliable and effective results while providing a high purity level. By microencapsulating these molecules, we are able to protect them and preserve the APIs while increasing their bioavailability and the potential therapeutic benefits for a variety of pharmaceutical applications.”

Diversified Products and Patents

To date, AXIM has formulated over 20 diversified products and possess two patents, 12 patent applications, seven registered trademarks, 15 trademark applications already allowed, and 5 pending trademark applications in the U.S. These include AXIM’s proprietary chewing gum products CanChew+® and MedChew Rx® which have been developed to treat IBS symptoms and the treatment of pain and spasticity associated with MS, respectively.

“At AXIM, we’re committed to best practices and innovation, and the fact that we can apply this new and fully cGMP compliant process to a number of applications is very exciting,” said Anastassov. “We’re confident that our work in developing both these cGMP methods, along with our diversified delivery systems and products, will expand the pharmaceutical cannabinoid market and broaden the potential areas of application based on specific indications.”




AXIM® Biotechnologies, Inc. (AXIM) focuses on the research, development and production of cannabinoid-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew+®a CBD-based controlled release chewing gum, CanChew+ 50®, containing 50 mg of CBD undergoing clinical trials in patients with IBS and MedChew Rx®, a combination CBD/THC gum that will undergo clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. AXIM has several products developed or in developmental stage for treatment and/ or prevention of multiple conditions and symptoms. We prioritize the well-being of our customers while embracing a solid fiscal strategy.

For more information, please visit


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.


AXIM [(R)] Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

This article originally appeared on Dividend Investments.

Leave a reply

Your email address will not be published. Required fields are marked *


  • A Girl Got Electrocuted While Swimming
  • Sydney bus driver smashed wall
  • Treasurer Joe Hockey concedes $7 Medicare co-payment is a tax on Q and A program
  • Father Of Three Killed By A Gang In A Brutal Ambush